Education
About Us
Working with TipRanks
Follow Us
Regeneron (REGN)
NASDAQ:REGN
Earnings Data
Report Date
Jul 31, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
8.53Last Year’s EPS
11.56Same Quarter Last Year
Moderate Buy
Based on 23 Analysts Ratings
Earnings Call Summary
Earnings Call Date:Apr 29, 2025
|% Change Since: -20.80%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture with strong growth in key products like Dupixent and promising pipeline advancements. However, significant challenges were highlighted, including a decline in EYLEA sales, regulatory delays for EYLEA HD, and issues with patient assistance funding. Financial stability remains strong, but the balance of highlights and lowlights points to ongoing challenges that need to be addressed.Company Guidance
During Regeneron's First Quarter 2025 earnings call, guidance was provided on several key metrics and business areas. EYLEA's U.S. net sales were reported at $736 million, reflecting a 39% year-over-year decline, impacted by increased competition and reduced wholesale inventory levels. However, EYLEA HD saw a 54% increase in U.S. sales to $307 million. Dupixent's global net sales grew by 20% year-over-year, reaching $3.7 billion, driven by robust demand across approved indications. Libtayo's U.S. sales rose 21% to $193 million, with its global sales growing 8% to $285 million. Regeneron highlighted an updated 2025 gross margin guidance range of 86% to 87%, reflecting higher-than-expected inventory write-offs. The company also discussed its continued investment in R&D, with approximately 45 product candidates in clinical development and anticipated data readouts and regulatory approvals expected throughout the year.Strong Growth in Dupixent Sales
First quarter 2025 net product sales for Dupixent grew 20% globally on a constant currency basis compared to the first quarter of 2024. In the U.S., sales grew 19%.
Libtayo's Market Performance
Libtayo in the U.S. grew 21% compared to the first quarter of last year and has increased its share in the lung cancer market.
Pipeline Advancements
Regeneron's pipeline includes approximately 45 product candidates with significant investments in R&D. Anticipated U.S. regulatory approvals for several drugs in 2025.
Sanofi Collaboration Revenue
Revenues from the Sanofi collaboration were approximately $1.2 billion, with Regeneron's share of profits growing 27% versus the prior year.
Positive Financial Position
Regeneron generated $816 million in free cash flow in the first quarter and ended the quarter with cash and marketable securities of $17.6 billion.
REGN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
REGN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 29, 2025 | $609.96 | $568.07 | -6.87% |
Feb 04, 2025 | $665.01 | $695.13 | +4.53% |
Oct 31, 2024 | $920.25 | $835.89 | -9.17% |
Aug 01, 2024 | $1076.22 | $1090.13 | +1.29% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Regeneron (REGN) report earnings?
Regeneron (REGN) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
What is Regeneron (REGN) earnings time?
Regeneron (REGN) earnings time is at Jul 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is REGN EPS forecast?
REGN EPS forecast for the fiscal quarter 2025 (Q2) is 8.53.
